<DOC>
	<DOCNO>NCT00819143</DOCNO>
	<brief_summary>Although allogeneic stem cell transplantation curative CML , evidence BCR-ABL oncogene low level still find long-term follow-up survivor . Such low level BCR-ABL post-transplant fulfill criterion molecular relapse monitor regularly consider suppressed GVL effect . Treatment donor lymphocyte infusion institute quantifiable BCR-ABL transcript level rise steadily , indicative true molecular relapse . Similarly , BCR-ABL still detectable majority CML patient treat imatinib achieve complete cytogenetic response , although amount BCR-ABL transcript seem decline long follow-up . With 5 year follow-up CML patient CP receive imatinib , estimate cumulative best rate complete hematologic response complete cytogenetic response 98 percent 87 percent , respectively10 . For minority CP-CML patient respond satisfactorily imatinib , second-generation tyrosine kinase inhibitor recommend next line treatment . A major question face clinician whether imatinib pharmacologically potent second-generation tyrosine kinase inhibitor ; suppress CML clone leukemic stem cell level effectively allogeneic stem cell transplantation . This protocol design scientifically compare treatment response patient treat allogeneic stem cell transplantation patient receive imatinib second generation tyrosine kinase inhibitor . The primary endpoint trial proportion patient detect minimal residual disease ( DMRD ) primitive CD34 plus progenitor subpopulation earlier 60 day onset respective treatment .</brief_summary>
	<brief_title>Collection Blood Bone Marrow Samples From Select Patients With CML Measure Minimal Residual Disease</brief_title>
	<detailed_description>Although allogeneic stem cell transplantation curative CML , evidence BCR-ABL oncogene low level still find long-term follow-up survivor . Such low level BCR-ABL post-transplant , fulfill criterion molecular relapse monitor regularly consider suppressed GVL effect . Treatment donor lymphocyte infusion institute quantifiable BCR-ABL transcript level rise steadily , indicative true molecular relapse . '' Similarly , BCR-ABL still detectable majority CML patient treat imatinib achieve complete cytogenetic response , although amount BCR-ABL transcript seem decline long follow-up . With 5 year follow-up CML patient CP receive imatinib , estimate cumulative best rate complete hematologic response complete cytogenetic response 98 percent 87 percent , respectively 10 . For minority CP-CML patient respond satisfactorily imatinib , second-generation tyrosine kinase inhibitor recommend next line treatment . A major question face clinician whether imatinib pharmacologically potent second-generation tyrosine kinase inhibitor suppress CML clone leukemic stem cell level effectively allogeneic stem cell transplantation . This protocol design scientifically compare treatment response patient treat allogeneic stem cell transplantation patient receive imatinib second generation tyrosine kinase inhibitor . The primary endpoint trial proportion patient detect minimal residual disease ( DMRD ) primitive CD34 plus progenitor subpopulation earlier 60 day onset respective treatment .</detailed_description>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Diagnosed CML 2 . Age 18 year old EXCLUSION CRITERIA : 1 . Less 60 day onset CML direct treatment 2 . Unable comprehend investigational nature protocol participation unable sign consent document . 3 . Platelet count less 50 time 10 ( 9 ) /L ( Bone marrow donor ) 4 . Pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 13, 2011</verification_date>
	<keyword>Tissue Procurement</keyword>
	<keyword>Sample Collection</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
	<keyword>Laboratory Research</keyword>
</DOC>